National Health Research Institutes

ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration

Retrieved on: 
Thursday, August 3, 2023
GMP, Good manufacturing practice, National Health Research Institutes, Medical device, Marketing, ISO, Hsinchu Biomedical Science Park, Ophthalmology, NHRI, TGA, International Organization (journal), Neurology, ChromeOS, Pharmaceutical industry

The plan, proposed by ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation, is to upgrade Vitargus’® manufacturing processes so that ultimately, it can handle the global market supply of Vitargus®.

Key Points: 
  • The plan, proposed by ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation, is to upgrade Vitargus’® manufacturing processes so that ultimately, it can handle the global market supply of Vitargus®.
  • The factory is located in Hsinchu Biomedical Science Park, Taiwan and BioFirst Corporation is targeting to complete the construction in 2024.
  • BioFirst Corporation is dedicated to researching, developing, manufacturing, marketing, and securing exclusive global rights for innovative patented medical products.
  • Obtaining necessary Medical Devices GMP and International Organization for Standardization (ISO) certifications is ABVC’s priority, reinforcing our commitment to quality and compliance."

GLOBAL PHARMACEUTICAL LEADER SETS SIGHT ON SUSTAINABLE FUTURE FOR THE SECTOR BY SETTING CHALLENGING SBTI NET ZERO TARGET

Retrieved on: 
Tuesday, June 6, 2023
Science, Science Based Targets initiative, General counsel, Sustainability reporting, Silent Scope 2, PwC, Electricity, GHG, Carbon, 2015 United Nations Climate Change Conference, Patient, National Health Research Institutes, Climate, ESG, Policy, Supply, CO2, Renewable energy, Carbon accounting

BASILDON, England, June 6, 2023 /PRNewswire/ -- Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced increased targets to divert 40% of its air shipments to sea in 2023, and 75% by the end of 2028. 

Key Points: 
  • Pharmanovia has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report.
  • This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions.
  • Pharmanovia's Net-Zero goals have been validated by the Science-Based Target Initiative (SBTi).
  • "Our purpose is to improve the lives of patients globally, which is why setting meaningful targets to reduce our environmental impact is critical, to build a sustainable future for patients and the sector.

Biosimilars Global Market Report 2022: Rising Prevalence of Chronic Diseases Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Pharmaceutical, United Nations, Erythropoietin, Biocon, Infection, National Health Research Institutes, Growth, Patient, Application, Insulin, CAGR, Growth hormone, Insulin glargine, Maintenance, Cancer, Asthma, Immune system, PCP, Conditional sentence, Arthritis, COVID-19, Degenerative disease, Partnership, PricewaterhouseCoopers, Prevalence, Mylan, Awareness, Safety, Generic drug, Vaccine

The "Biosimilars Global Market Report 2022: By Product, By Types, By Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilars Global Market Report 2022: By Product, By Types, By Application" report has been added to ResearchAndMarkets.com's offering.
  • The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.
  • Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.
  • The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market.

DoIT of MOEA Created New Business Opportunities at TIE 2022

Retrieved on: 
Monday, October 17, 2022
Carbon, Physician, Time-invariant system, Medicine, Technology, Efficiency, Industrial Technology Research Institute, Biotechnology, Patient, Laser, Recycling, ITRI, NHRI, TIE, Multimedia, HAR, TSV, MOEA, Department, Laser speckle contrast imaging, Glass, National Health Research Institutes, Burn, Steel, Ministry, TGV, Digital, Exhibition, LCD, Industrial technology, Economy, Solution, Ministry of the economy, Doit, Renewable energy, Television, Online shopping

TAIPEI, Oct. 17, 2022 /PRNewswire/ -- The physical exhibition of Taiwan Innotech Expo 2022 (TIE 2022) has ended with great success. The Department of Industrial Technology (DoIT), Ministry of Economic Affairs (MOEA) curated the Discovering Technology Treasures exhibition at the Innovation Pilot pavilion, where 80 innovative technologies related to net-zero carbon emissions, sustainable development, electric cars, and biotechnology were on display. More than 40,000 visitors and nearly 100 companies participated in this event, sparking numerous business opportunities. In response to the call for net-zero emissions by 2050, many leading enterprises expressed their keen interest in solutions for carbon reduction and circular economy at the exhibition.

Key Points: 
  • TAIPEI, Oct. 17, 2022 /PRNewswire/ -- The physical exhibition of Taiwan Innotech Expo 2022 (TIE 2022) has ended with great success.
  • More than 40,000 visitors and nearly 100 companies participated in this event, sparking numerous business opportunities.
  • Two major highlights of the green solutions at TIE 2022 were the Laser-based Encapsulation Removal Process for LCD panels and the Digital Carbon-Emission Reduction Application Technology.
  • Among the smart healthcare solutions at TIE 2022 was the laser speckle contrast imaging (LSCI) system developed by the National Health Research Institute (NHRI).

DoIT focuses on electric vehicles and net-zero sustainable industries

Retrieved on: 
Friday, October 14, 2022
Hydrogen, Taipei, Technology, Efficiency, Technology transfer, Organization, Solution, Biotechnology, Patient, Hospital, Second Place, Ministry of Economic Affairs (Taiwan), Laser speckle contrast imaging, PCCU, ITRI, NHRI, World Trade Center, Multimedia, Institute, Information industry, Industry, Department, National Health Research Institutes, AI, World, Industrialisation, Burn, Ministry, Industrial technology, Economy, NTU, Doit, Fine chemical

TAIPEI, Oct. 13, 2022 /PRNewswire/ -- The Department of Industrial Technology (DoIT) under the Ministry of Economic Affairs today (Oct 13) kicked off the Discovering Technology Treasures exhibit at the Innovation Pilot pavilion at the 2022 Taiwan Innotech Expo. The exhibit, at the Taipei World Trade Center Hall 1,  features 80 innovative technologies that will drive the transformation and upgrading of Taiwan industry. These technologies, focusing on electric vehicles, net-zero sustainability, and biotechnology & medical care, have been selected from hundreds of achievements of technology development programs carried out by 14 non-profit R&D organizations, including ITRI, Institute for Information Industry, and National Health Research Institutes (NHRI). These organizations will work with domestic and foreign companies, incubating start-up teams and linking up with international markets, thereby successfully realizing a number of cooperation projects and forging new business opportunities for industry.

Key Points: 
  • DoIT Director General Chiou Chyou-Huey commented that the 80 technologies featured at the Discovering Technology Treasures exhibit have two major characteristics.
  • Secondly, these technologies will, on the basis of entrepreneurial thinking, help to cultivate new industries that can spark start-ups and business opportunities.
  • This is Taiwan's first example of successfully combining a vehicle controller and wire-based controller, and this technology serves as the core in enabling electric vehicles to start smoothly.
  • Many other innovative technologies promoted by the DoIT and being shown at the Taiwan Innotech Expo will promote new business opportunities in the biotechnology and medical care industries.

Global Oncology Biosimilars Market (2022 to 2031) - Featuring Pfizer, Amgen and Hospira Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Health, Oncology, Cancer, Patent, Granulocyte colony-stimulating factor, PricewaterhouseCoopers, Growth, Colorectal cancer, Research, Medicine, Prescription, PCP, Immune system, Multiple myeloma, Center, Safety, R, Awareness, Lymphatic system, Breast cancer, National Health Research Institutes, Large-cell lung carcinoma, Fine chemical, Generic drug

The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF).

Key Points: 
  • The main drug types of oncology biosimilars are monoclonal antibody, immunomodulators, hematopoietic agents and granulocyte colony-stimulating factor (G-CSF).
  • The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.
  • The lack of awareness on biosimilars among primary care physicians (PCPs) and specialist limits the growth of the oncology biosimilars market.
  • Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.

PharmaTher Announces Publication of Research Data for KETABET™

Retrieved on: 
Tuesday, January 4, 2022
Twitter, Pharmacotherapy, Post-traumatic stress disorder, Addiction, Anesthesia, Substance abuse, Suicidal ideation, FDA, Amyotrophic lateral sclerosis, GLOBE, OTCQB, Lists of diseases, NMDA, Company, Government budget balance, Betaine, Pain, Holding, USP, Pain disorder, Mental health, Depression, Composition, Patient, Mouse, Chronic pain, Patent, CSE, LTP, LinkedIn, Method, National Health Research Institutes, Biomedicine & Pharmacotherapy, Pharmaceutical industry, Ketamine

TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a life sciences company focused on the development and commercialization of specialty ketamine prescription-based products, today announced the publication of a scientific article demonstrating the potential of KETABET™, a patented combination formulation of FDA-approved ketamine and betaine anhydrous, to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain. The article titled, "Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice", is published in Biomedicine & Pharmacotherapy and can be found here.

Key Points: 
  • Based on the outcome from the ongoing observational studies, the Company will advance the KETABET program with its microneedle patch technology in Phase 2 clinical studies in H2-2022.
  • The present published study aimed to assess whether repeated co-treatment with betaine and ketamine improved behavioral impairments and hippocampal synaptic plasticity.
  • As such, we remain focused on expanding our clinical programs with KETABET for FDA approval.
  • PharmaTher has an exclusive license agreement with the National Health Research Institutes to develop and commercialize of the intellectual portfolio protecting KETABET, the patent titled "Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine".

PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

Retrieved on: 
Tuesday, December 21, 2021
University, Twitter, GLOBE, OTCQB, National Health Research Institutes, FDA, Trial of the century, University of Kansas Medical Center, Invention, ALS, LTS, Anesthesia, LinkedIn, CGMP, CSE, Mental health, IND, Levodopa-induced dyskinesia, Life expectancy, USP, Betaine, Esketamine, Safety, Research, Holding, Disease, Pharmacokinetics, Movement disorders, Ketamine, Program, Depression, Company, LID, Substance-related disorder, Abbreviated New Drug Application, QUB, Patient, Pharmaceutical industry

TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, is pleased to provide a product pipeline update and expected milestones for 2022.

Key Points: 
  • TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the Company or PharmaTher) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, is pleased to provide a product pipeline update and expected milestones for 2022.
  • We are now in a position both operationally and financially to seek FDA approval for KETARX, our ketamine prescription product, and to enter clinical studies for KETAPATCH, our ketamine patch product, in 2022.
  • PharmaTher has an exclusive license agreement with the University of Arizona for the intellectual property protecting the potential use of ketamine to treat movement disorders.
  • During this analysis, it was observed that the patients experienced an improvement in LID lasting several weeks beyond treatment [Sherman et al, 2016].

Global Biosimilars Market Analysis & Forecasts, 2015-2020, 2020-2025F, & 2030F Featuring Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's, Boehringer Ingelheim, Elli Lilly and Co, Mylan N.V., Sanofi - ResearchAndMarkets.com

Retrieved on: 
Monday, December 13, 2021
Health, Pharmaceutical, Conditional sentence, Company, Erythropoietin, PCP, Growth hormone, Celltrion, Awareness, Growth, Degenerative disease, National Health Research Institutes, COVID-19, Cancer, Insulin, PricewaterhouseCoopers, Pfizer, Safety, Patient, Arthritis, Immune system, Patent, Prevalence, Infection, Boehringer Ingelheim, Sanofi, Amgen, Cheplapharm Arzneimittel, Diabetes, Asthma, Stada Arzneimittel, Fine chemical, Generic drug, Vaccine, Biocon

Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel.

Key Points: 
  • Major players in the biosimilars market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel.
  • The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer.
  • The lack of awareness about biosimilars among primary care physicians (PCPs) and specialists limits the growth of the biosimilars market.
  • Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.

PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

Retrieved on: 
Tuesday, November 30, 2021
Patient, Patent, Trial of the century, Mental health, Company, Plasma, Post-traumatic stress disorder, Confusion, Compliance, Seizure, Needle, Hallucination, Holding, National Health Research Institutes, Tic disorder, CSE, Chronic pain, Pain, Lists of diseases, Homocysteine, Research, GLOBE, Japan Patent Office, Betaine, Depression, OTCQB, Composition, FDA, Infection, Homocystinuria, Amnesia, Method, Japanese patent law, Pharmaceutical industry

The granted patent strengthens the Companys global patent portfolio and it provides for broad potential of KETABET for uses in various mental health, neurological and pain disorders, as well as novel delivery forms such as with the Companys patented hydrogel-forming microneedle patch delivery system.

Key Points: 
  • The granted patent strengthens the Companys global patent portfolio and it provides for broad potential of KETABET for uses in various mental health, neurological and pain disorders, as well as novel delivery forms such as with the Companys patented hydrogel-forming microneedle patch delivery system.
  • The patent titled: "Method and Composition for Decreasing the Psychotomimetic Side Effect and Addictive Disorder of Ketamine" is expected to provide protection into 2036.
  • Patent families protecting KETABET under an exclusive worldwide license agreement with the National Health Research Institutes have also been issued inTaiwan (Patent no.
  • I648049), and the Company expects to convert the current patent applications in the U.S., Europe, Japan, Canada, Israel and China into granted patents.